Skip to main content
OpenTrials
Completed

NCT Number: NCT03978767

Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial

A randomized non-inferiority trial of women with preeclampsia with severe features to determine if the addition of nonsteroidal anti-inflammatory drugs is inferior or non-inferior to standard analgesic bundles in their impact on postpartum hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Barnes Jewish Hospital

St Louis, Missouri, 63110, United States

About this study

Recently published clinical guidelines for the care of women with hypertensive disorders recommended that nonsteroidal anti-inflammatory drugs (NSAIDs) should be withheld from patients with hypertension that persists for more than one day postpartum (1). This recommendation is based in data from the general medicine literature, which suggests a role of NSAIDs in precipitating hypertension in non-pregnant adults (2,3). It may also draw from previously published case reports of post-partum hypertension that were thought to be NSAID induced (4). There has been a paucity of data from the obstetric literature to support or rebuff this recommendation. As the opioid crisis worsens in the United States, additional attention and resources have focused on limiting the use of narcotic medications. The effective employment of non-opioid analgesics has been shown to reduce narcotic use (5). Ibuprofen and other NSAIDs are the most effective and most commonly prescribed analgesics for postpartum pain, but clinicians now find themselves stuck between these recommendations and their efforts to limit unnecessary opioid prescriptions.

The investigators propose a randomized controlled non-inferiority trial of women with preeclampsia comparing a postpartum analgesic protocol that includes NSAIDs, to one that excludes them. The central hypothesis is that NSAID use does not worsen hypertensive diseases of pregnancy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women at > 23 weeks gestational age undergoing vaginal or cesarean delivery at Barnes-Jewish Hospital with:
  • An antepartum diagnosis of preeclampsia with severe features
  • Pre-eclampsia with severe features will be defined as:
  • Elevated blood pressure ≥ 160/110, or
  • Pre-eclampsia in the setting of thrombocytopenia (platelet count < 100,000), or
  • Impaired liver function (AST elevated to twice upper limit of normal), or
  • Persistent epigastric pain, or
  • Renal insufficiency (serum creatinine of 1.1 mg/dl or doubling of prior value), or
  • Pulmonary edema, or
  • New onset visual disturbance or headache unresponsive to therapy.

Exclusion criteria

  • NSAID allergy
  • Allergy to acetaminophen
  • Antihypertensive use in this pregnancy prior to 20 weeks gestation
  • Chronic kidney disease or Acute kidney injury with Creatine clearance less than 60 mL/min
  • Inability to obtain consent
  • Opioid abuse disorder
  • Peptic ulcer disease.

Treatment and study plan

Ibuprofen 600 mg

Drug

NSAID pain medication to be used in the experimental bundle for postpartum analgesia

Ketorolac

Drug

NSAID analgesic to be used in the experimental bundle for postpartum analgesia in patients who underwent cesarean section

Acetaminophen

Drug

Analgesic medication to be used in both treatment arms

Oxycodone

Drug

Analgesic medication to be used in both treatment arms

Primary outcomes

  1. postpartum antihypertensive requirements

    Time frame: at the end of hospitalization, up to 7 days after randomization

    measurement of anti-hypertensive requirements at time of discharge

Secondary outcomes

  1. Postpartum pain scores

    Time frame: From randomization to 6 weeks after randomization

    Evaluate the effect of NSAIDs on patient perception of pain

  2. Postpartum opioid use

    Time frame: From randomization to 6 weeks after randomization

    Compare the opioid requirements in each arm

  3. Mean arterial blood pressure

    Time frame: From randomization to 6 weeks after randomization

    Compare peak, average and median MAPs postpartum

  4. End organ damage

    Time frame: during hospitalization, an average of 4 days

    Evaluate for evidence of renal, hepatic or neurological injury in the poatpartum period

  5. Hospital readmission

    Time frame: From randomization to 6 weeks after randomization

    Evaluate the incidence of hospital readmission rate postpartum

  6. Continued anti-hypertensive requirement

    Time frame: up to 6 weeks

    evaluate the need for antihypertensive medications at 6 weeks postpartum

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Registry information

Official study title

Preeclampsia And Nonsteroidal Drugs for Analgesia (PANDA): a Randomized Non Inferiority Trial

Acronym: PANDA

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Jun 7, 2019
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.